Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

ZVRA - Zevra Therapeutics, Inc. Financial... | Finranks

Home

/

ZVRA

Z

Zevra Therapeutics, Inc. (ZVRA)

NMS – Real Time Price. Currency in USD

11.42

+0.08 (0.71%)

Market open: Aug 12, 2026, 2:47 PM EDT

11.77

+0.43 (3.79%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Total Assets

Total Liabilities

Stockholders Equity

Total Debt

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

106M

24M

27M

10M

Cost of goods sold

-21M

-20M

-4M

-1M

Gross Profit

86M

4M

24M

9M

Operating expenses (excl. COGS)

-90M

-91M

-73M

-34M

Operating Income

-4M

-87M

-50M

-25M

Non-operating income, total

91M

-3M

4M

-2M

Pretax income

87M

-90M

-46M

-27M

Equity in earnings

0

0

0

0

Taxes

-3M

-15M

0

33K

Non-controlling/minority interest

0

0

0

0

After tax other income/expense

-6M

0

0

0

Net income before discontinued operations

78M

-106M

-46M

-27M

Discontinued operations

0

0

0

0

Net income

78M

-106M

-46M

-27M

Dilution adjustment

0

0

0

0

Preferred dividends

0

0

0

0

Name

2025

2024

2023

2022

Total assets

285M+59.8%

178M+3.4%

172M+49.4%

115M

Total current assets

223M

86M

87M

93M

Total non-current assets

62M

92M

85M

23M

Total liabilities

130M-6.1%

138M+25.3%

110M+174.6%

40M

Total current liabilities

39M

34M

74M

12M

Total non-current liabilities

91M

104M

37M

28M

Total equity

155M

40M

62M

75M

Total liabilities & shareholders' equities

285M

178M

172M

115M

Total debt

63M+4.8%

60M+37.8%

44M+209.8%

14M

Name

2025

2024

2023

2022

Cash from operating activities

-2M

-70M

-34M

-19M

Cash from investing activities

18M

-22M

-17M

-37M

Cash from financing activities

12M

82M

28M

8M

Free cash flow

-2M+96.5%

-70M-105.9%

-34M-79.9%

-19M